Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Down 5.4% in January

Carisma Therapeutics, Inc. (NASDAQ:CARM) was the recipient of a significant decline in short interest in January. As of January 15th, there was short interest totalling 537,700 shares, a decline of 5.4% from the December 31st total of 568,400 shares. Based on an average daily volume of 252,500 shares, the short-interest ratio is presently 2.1 days. Currently, 2.5% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on CARM. Baird R W lowered Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. HC Wainwright reaffirmed a “neutral” rating on shares of Carisma Therapeutics in a report on Monday, December 16th. Evercore ISI reissued an “in-line” rating and issued a $0.70 price target (down from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. Robert W. Baird cut shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $10.00 to $1.00 in a research note on Thursday, December 12th. Finally, D. Boral Capital reissued a “buy” rating and set a $12.00 target price on shares of Carisma Therapeutics in a research note on Monday, January 13th. Five investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.94.

Institutional Investors Weigh In On Carisma Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Barclays PLC grew its stake in shares of Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after buying an additional 549,290 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Carisma Therapeutics in the second quarter valued at approximately $40,000. Finally, Wexford Capital LP grew its position in Carisma Therapeutics by 75.5% in the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after acquiring an additional 15,000 shares in the last quarter. 44.27% of the stock is owned by hedge funds and other institutional investors.

Carisma Therapeutics Stock Performance

Shares of Carisma Therapeutics stock opened at $0.46 on Friday. Carisma Therapeutics has a 12 month low of $0.38 and a 12 month high of $2.77. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 1.39. The stock has a market cap of $19.20 million, a PE ratio of -0.29 and a beta of 1.56. The business has a fifty day simple moving average of $0.54 and a 200-day simple moving average of $0.85.

Carisma Therapeutics (NASDAQ:CARM) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, hitting the consensus estimate of ($0.31). The business had revenue of $3.39 million during the quarter. Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. On average, sell-side analysts anticipate that Carisma Therapeutics will post -1.32 EPS for the current fiscal year.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.